Biotech Values

[DewDiligence]

Alphaeon won't have to worry about dilution unless EOLS performs even worse than I expect. EOLS has tacitly acknowledged that they will lose significant money in 2019*, but they ought to at least break even in 2020.

*

$EOLS —The simple explanation for non-guidance is they expect to lose more $ in 2019 than they want investors to know about.(As you know,I don't think much of their biz model.)

Non-launch of Jeuveau 2mo post-approval (on 2nd review cycle) is bizarre—not sure what 2make of it.

— Roy Friedman (@DewDiligence) March 18, 2019